ASKA Pharmaceutical Holdings Co Ltd
TSE:4886
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
ASKA Pharmaceutical Holdings Co Ltd
Net Income (Common)
ASKA Pharmaceutical Holdings Co Ltd
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ASKA Pharmaceutical Holdings Co Ltd
TSE:4886
|
Net Income (Common)
¥5.1B
|
CAGR 3-Years
6%
|
CAGR 5-Years
51%
|
CAGR 10-Years
N/A
|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Net Income (Common)
¥112.9B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Net Income (Common)
¥304.6B
|
CAGR 3-Years
72%
|
CAGR 5-Years
34%
|
CAGR 10-Years
-1%
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Net Income (Common)
¥363.2B
|
CAGR 3-Years
39%
|
CAGR 5-Years
20%
|
CAGR 10-Years
14%
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Net Income (Common)
¥452.2B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
17%
|
CAGR 10-Years
22%
|
|
|
Astellas Pharma Inc
TSE:4503
|
Net Income (Common)
¥322.9B
|
CAGR 3-Years
33%
|
CAGR 5-Years
18%
|
CAGR 10-Years
6%
|
|
ASKA Pharmaceutical Holdings Co Ltd
Glance View
ASKA Pharmaceutical Holdings Co., Ltd. engages in the management of its group companies which are involved in the manufacture and sale of pharmaceuticals, quasi-drugs, food, veterinary drugs, feeds, feed additives, and medical devices. The company is headquartered in Minato-Ku, Tokyo-To. The company went IPO on 2021-04-01. The firm mainly operates in two business segments. The Pharmaceutical segment is mainly engaged in the manufacture, purchase and sale of pharmaceutical products. The Others segment is involved in the manufacture of veterinary drugs, the provision of clinical testing services, the outsourcing of testing services, the purchase and sale of medical equipment, as well as the sale of health foods.
See Also
What is ASKA Pharmaceutical Holdings Co Ltd's Net Income (Common)?
Net Income (Common)
5.1B
JPY
Based on the financial report for Mar 31, 2025, ASKA Pharmaceutical Holdings Co Ltd's Net Income (Common) amounts to 5.1B JPY.
What is ASKA Pharmaceutical Holdings Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
51%
Over the last year, the Net Income (Common) growth was -32%. The average annual Net Income (Common) growth rates for ASKA Pharmaceutical Holdings Co Ltd have been 6% over the past three years , 51% over the past five years .
